Hoxton Planning & Management LLC Increases Stake in Pfizer Inc. (NYSE:PFE)

Hoxton Planning & Management LLC raised its holdings in Pfizer Inc. (NYSE:PFE) by 73.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 16,728 shares of the biopharmaceutical company’s stock after purchasing an additional 7,097 shares during the period. Hoxton Planning & Management LLC’s holdings in Pfizer were worth $464,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of PFE. VisionPoint Advisory Group LLC boosted its stake in shares of Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 1,047 shares during the last quarter. GoalVest Advisory LLC boosted its stake in shares of Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 811 shares during the last quarter. Creekmur Asset Management LLC acquired a new stake in shares of Pfizer in the fourth quarter worth approximately $32,000. Tennessee Valley Asset Management Partners acquired a new stake in shares of Pfizer in the fourth quarter worth approximately $36,000. Finally, DiNuzzo Private Wealth Inc. acquired a new stake in shares of Pfizer in the fourth quarter worth approximately $37,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. BMO Capital Markets reissued an “outperform” rating and set a $36.00 price objective (up previously from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research report on Monday, June 17th. Finally, Morgan Stanley boosted their price objective on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a report on Thursday, May 2nd. Ten research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, Pfizer presently has a consensus rating of “Hold” and a consensus target price of $35.86.

Pfizer Stock Performance

Shares of NYSE PFE traded down $0.20 during trading hours on Wednesday, reaching $27.79. The stock had a trading volume of 5,351,377 shares, compared to its average volume of 40,864,168. The firm has a market cap of $157.47 billion, a price-to-earnings ratio of -462.92, a PEG ratio of 1.10 and a beta of 0.70. The company has a current ratio of 1.05, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $37.80. The firm has a 50-day moving average of $27.77 and a 200-day moving average of $27.69.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, beating the consensus estimate of $0.56 by $0.26. The firm had revenue of $14.88 billion during the quarter, compared to the consensus estimate of $13.87 billion. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The firm’s revenue was down 19.5% compared to the same quarter last year. During the same period in the prior year, the business earned $1.23 EPS. Equities research analysts predict that Pfizer Inc. will post 2.38 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, June 14th. Stockholders of record on Friday, May 10th were paid a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.05%. The ex-dividend date was Thursday, May 9th. Pfizer’s dividend payout ratio (DPR) is -2,799.53%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.